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Abstract 
Background: Lipids play different important roles in central nervous system so that dysregulation of lipid pathways 
has been implicated in a growing number of neurodegenerative disorders including multiple sclerosis (MS). MS is the 
most prevalent autoimmune disorder of the central nervous system, with neurological symptoms caused by inflam-
mation and demyelination. In this study, a lipidomic analysis was performed for the rapid profile of CD4+ T lympho-
cytes from MS patient and control samples in an untargeted approach.
Methods: A matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry based 
approach was used for the analysis of lipid extracts using 9-aminoacridine as matrix. Lipids were analyzed in negative 
mode and selected species fragmented using MALDI tandem mass spectrometry for their structural assignments.
Results: The analysis reveals some modifications in the phospholipid pattern of MS CD4+ T lymphocytes with 
respect to healthy controls with a significant increase of cardiolipin species in MS samples.
Conclusions: These results demonstrate the feasibility of a MALDI-TOF approach for the analysis of CD4+ lipid 
extracts and suggest how alterations in the lipid metabolism characterized lymphocytes of MS patients.
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Background
Multiple sclerosis (MS) is a demyelinating inflammatory 
disease of the central nervous system (CNS) with hetero-
geneous clinical outcomes [1]. The causes of MS are not 
well understood but there is compelling evidence that a 
combination of factors such as environment, viruses and 
dietary conditions, in conjunction with genetic suscepti-
bility might drive an autoimmune response against struc-
ture of CNS. Autoimmune mechanisms of CNS damage 
are primarily mediated by auto-reactive CD4+ T cells, 
which are specific for encephalitogenic epitopes of mye-
lin peptides [2].
Migration of autoimmune T cells from the periphery 
into CNS parenchyma leads to inflammation, demyeli-
zation and damage of axons, oligodendrocytes and neu-
rons [1]. This autoimmune T cell mediated tissue damage 
results in an impairment of motor function leading to 
paralysis. Disease is progressive and often takes a relaps-
ing-remitting course. Progression and severity of the 
disease as well as types of CNS lesions are highly hetero-
geneous among patients with MS [2].
T lymphocytes play a central role in the pathogenesis of 
MS [2] and many successfully therapies in MS have been 
used T cell target approaches [3]. T cells are found in all 
four of the described histopathologic subtypes of MS [4]. 
Both CD4+ T and CD8+ T cells have been demonstrated 
in MS lesions, with CD4+ T cells predominating in acute 
lesions and CD8+ T cells being observed more frequently in 
chronic lesions [4]. It has been reported that CD4+ T lym-
phocytes MHC class II-restricted, mainly polarized as Th1 
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cells induced CNS inflammation by producing inflamma-
tory cytokines such as IFN-γ, IL-2, TNF-α and lymphotoxin 
[5]. Activated myelin-reactive CD4+ T cells are present in 
the blood and cerebrospinal fluid of MS patients [4].
A main feature of MS is the change in the trafficking prop-
erties of immune cells throughout the blood–brain barrier 
[6]. CD4+ cells, positive for PSGL-1 surface antigen, were 
found to transmigrate throughout the blood–brain barrier 
to levels significantly higher than the equivalent popula-
tion isolated from healthy subjects [7]. Moreover, inhibiting 
leukocyte adhesion to blood–brain barrier by antibodies 
against α4-integrin reduced the number of lesion in CNS 
of MS patients [8]. Regardless of the complexities associ-
ated with MS pathogenesis, the infiltration of immune cells 
and their activities likely contribute to the loss of myelin and 
axonal degradation that accompanies progression of the dis-
ease. Therefore, it is critical to understand the mechanisms 
involved in the transmigration of leukocytes into regions of 
the CNS where they are normally excluded.
Membrane lipid composition plays an important role 
in the dynamic of cells. In particular, changes in mem-
brane lipid composition that alter membrane fluidity 
may induce modifications in the functions of proteins 
and receptors involved in signaling pathways. Immune 
cell membrane lipids are involved in many functions and 
fatty acid abnormalities have been reported in immune 
cells from patients with MS [9]. Studies have provided 
that a specific lipid modification by peroxidative mecha-
nisms could be a significant pathogenic factor in MS [10]. 
Moreover changes in lipid composition of cerebral fluid 
and plasma, in MS, have been demonstrated [11].
Recently, developments in lipid mass spectrometry 
provided the ability to describe changes in lipid com-
positions that occur with disease progression or after a 
specific treatment, giving also the opportunity to identify 
lipid biomarkers and clarify cellular metabolism of indi-
vidual lipid species [12].
In the present study, we applied a mass spectrometry-
based lipidomics profiling to identify molecular lipid 
species associated with MS. To perform this, the lipid 
composition of human CD4+ T cells isolated from a 
cohort of MS patients and normal subjects was screened 
by Matrix-Assisted Laser Desorption Ionization Time-
of-Flight/Time-of-Flight (MALDI-TOF/TOF) analysis. 
Multivariate statistical analysis revealed that significant 
differences of specific lipid species characterize MS 
patients compared with normal subjects.
Methods
Ethical permission
The study was approved by the Vito Fazzi Hospital Eth-
ics Committee (ASL_LE-General Manager Resolution n 
228, February 11, 2014). Informed consent was obtained 
from each patient prior to entry into the study, according 
to the declaration of Helsinki.
Participants/study population
Height consenting patients suffering from defined relaps-
ing-remitting type of MS (RR-MS) with an age range of 
18–40  years, were clinically diagnosed at the Vito Fazzi 
Hospital in Lecce, and included into the study. Patients 
had a definite diagnosis of MS, as defined by the revised 
McDonald Criteria [13], and were classified as having 
relapsing remitting MS (RRMS) according to the Lublin-
Rheingold classification [14]. For the evaluation of dis-
ease severity the Expanded Disability Status Scale (EDSS) 
was used [15]. The characteristics of both MS and healthy 
donors are reported in the Table 1. None of the patients 
was on treatment with interferon, steroids or other 
immunosuppressive drugs for at least 3  months prior 
to entering the study. For each patient, blood samples 
were obtained at baseline; samples were also collected 
from a number of 5 healthy controls with an age range of 
28–48 years and used for the following analysis.
Chemicals
Solvents were reagent grade and purchased from Baker. 
9-aminoacridine (9-AA) matrix and cardiolipin stand-
ard (from bovine heart) were purchased from Sigma. 
Ficoll-Paque PLUS was GE healthcare life sciences. CD4+ 
T Cell Isolation Kit was from Miltenyi Biotec (Bergisch 
Gladbach, Germany).
Cell isolation
Venous blood from consenting participants was collected 
into anti-coagulant EDTA tubes (Beckman Coulter, 
Table 1 Clinical characteristics for  the multiple sclerosis 
(MS) and healthy control (HC) groups
RRMS relapsing remitting MS, EDSS Expanded Disability Status Scale, na not 
applicable.
No. Sex Age (years) Diagnosis/classification EDSS
MS1 M 35 RRMS 1.5
MS2 F 32 RRMS 3.5
MS3 F 27 RRMS 2.5
MS4 F 18 RRMS 3.0
MS5 F 35 RRMS 1.7
MS6 F 24 RRMS 3.9
MS7 M 35 RRMS 2.0
MS8 M 40 RRMS 2.3
HC1 M 37 Healthy control na
HC2 F 28 Healthy control na
HC3 F 30 Healthy control na
HC4 M 48 Healthy control na
HC5 F 32 Healthy control na
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South Africa). Plasma samples were obtained from 
patients with MS and from healthy controls (HC). PBMC 
fractions were isolated from whole blood using Ficoll-
Paque density-gradient centrifugation as described [16]. 
CD4+ T cells were purified by negative selection using an 
indirect magnetic cell sorting kit.
Lipid extraction from CD4+ T lymphocytes
The extraction of lipids from CD4+ T lymphocytes was 
performed using the method of Bligh and Dyer [17]. 
Briefly, to 20 μl (about 30 μg of protein) of cell suspen-
sion was added a solution of chloroform/methanol (1:2, 
v/v) and, after vigorous stirring, the final mixture was 
kept at 4°C and then centrifuged at 19,800×g for 5 min. 
To the supernatant obtained after centrifugation was 
added chloroform and a 5% (w/v) solution of NaCl. The 
mixture was stirred and placed at 4  °C for a time suffi-
cient to obtain the formation of two phases, the lower 
phase (chloroform) containing lipids and the upper aque-
ous phase (water and methanol). The chloroform phase 
was then collected, filtered through nylon filters, brought 
to dryness under a stream of nitrogen and then resus-
pended in an appropriate volume of chloroform for the 
subsequent analyses.
Fatty acid analysis
Fatty acid composition of CD4+ T cells was determined 
processing the samples as in [18]. Briefly, 20  μl of cell 
suspension (about 30  μg protein) was subjected to 
saponification for 90 min at 85–90°C using an alcoholic 
solution of KOH. After acidification of the mixture, the 
fatty acids were extracted with petroleum ether. The 
methyl esters of fatty acids (FAME) were prepared by 
heating the extract at 65°C for 30 min with a solution of 
boron trifluoride in methanol (17% BF3) and then ana-
lyzed by gas-chromatography. The helium carrier gas 
was used at a flow rate of 1 ml min−1. FAME were sepa-
rated on a 30 m × 0.32 mm HP5 (Hewlett Packard) capil-
lary column. The injector and detector temperature was 
maintained at 250°C. The column was operated isother-
mally at 150°C for 4 min, and then programmed to 250°C 
at 4°C/min. Peak identification was performed by using 
known standards and relative quantitation was automati-
cally carried out by peak integration.
MALDI‑TOF/TOF analysis
Lipids mass spectra were acquired in positive and nega-
tive ion reflector mode (detection range: 500–2,000 
mass/charge, m/z), using a Bruker Daltonics Ultraflex 
Extreme MALDI-TOF/TOF mass spectrometer. Sam-
ples were analyzed using 9-aminoacridine (9-AA) as a 
MALDI matrix. Matrix solution was prepared by dis-
solving 10  mg 9-AA in 2-propanol:acetonitrile (60:40 
v/v) (10  mg/mL) as reported [19]. Lipids, dissolved in 
the same matrix solvent, were mixed 1:1 with matrix and 
spotted on a MTP AnchorChip 384 target plate for mass 
analysis. Samples were allowed to air dry before inser-
tion into the MALDI-TOF analyzer. Before each data 
acquisition, an external calibration was conducted using 
the peptide standard calibration kit mixture (Bruker Dal-
tonics). For MALDI-MS and MS/MS analysis, ions from 
2000 consecutive laser shots were collected under reflec-
tron mode and summed into one spectrum. The col-
lected spectra were then processed with FlexAnalysis 3.4 
(Bruker Daltonics). A specific lipid database (Lipid Maps 
Database, http://www.lipidmaps.org) was used to facili-
tate and confirm the assignment of phospholipid species.
Statistical analysis
The data matrix was exported for partial least squares 
discriminant analysis (PLS-DA) using Simca-P+ 11.0 
software (Umetrics AB, Umeå, Sweden). Raw data were 
prepared to PLS-DA analysis through unit variance 
scaling (UV-scaling) and mean centering as default pre-
processing operations. To searching for the variables 
that have the greatest influence in class discrimination 
we used the Variable Importance Analysis in SIMCA-
P+. The software indicates that terms with large Vari-
able Importance in the Projection (VIP) value, larger 
than 1, are the most relevant for group’s discrimination. 
The major discriminant variables were selected and 
the possibly outlier values were searched by the online 
tool: outlier calculator (GraphPad Software) that per-
forms Grubbs’ test and setting a significance level of 
95% (alpha equal to 0.05). Subsequently, D’Agostino and 
Pearson omnibus normality test was performed in order 
to determine the normality of each variable measured in 
each group. When normality was accepted the Student’s 
t-test was employed, otherwise the Mann–Whitney 
U-test was used for comparing the groups. GraphPad 
Prism was used to perform all these univariate analyses 
(GraphPad software, Inc. USA). Finally, the differential 
significant variables were identified using Lipidmaps 
Database.
Results
MALDI‑TOF analysis and identification of lipids
Figure 1 shows the representative mass spectrum of total 
lipid extracts prepared from CD4+ T lymphocytes using 
9-AA as matrix. Lipids are charged molecules and due 
to presence of different charged groups, mass spectrom-
etry analysis of these molecules can be performed in both 
positive and negative ion mode. However, the process 
of ionization is not only dependent on lipid charge but 
also influenced by different factors including the matrix 
used for MALDI analysis [20, 21]. For this reason, lipids 
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extracts were analyzed in both negative and positive 
mode and results are shown in Figure 1a, b, respectively.
In the lower panel (Figure 1c, d) peaks corresponding 
to 9-AA alone, in positive and negative mode, are also 
showed. Their identification allowed excluding matrix 
peaks from the analysis of our lipid samples.
Although the number of matrix peaks detected was 
higher for 9-AA observed in negative mode, this ioni-
zation was found to be more efficient for the analysis of 
CD4+ lipids. In fact, if we compare the intensity of signals 
of the two spectra reported in Figure 1a, b, ionization in 
negative mode provided higher quality spectrum com-
pared to the positive one. The signal intensity and the 
number of peaks detected were both higher. These results 
correlate with previous studies reporting an increase in 
signal intensity in negative ion mode when using 9-AA 
matrix [20].
These observations demonstrated that better results 
were obtained using 9-AA in negative mode, and these 
experimental conditions were preferred for the analy-
sis of our samples. In Figure  2, spectra from healthy 
(Figure  2a) and MS (Figure  2b) subjects obtained with 
Figure 1 MALDI-TOF mass spectra of lipids from CD4+ T lymphocytes obtained in positive and negative mode. Representative MALDI-TOF mass 
spectra of lipids extracted from CD4+ T lymphocytes (upper panels) prepared by the Bligh and Dyer procedure. Spectra were acquired in both 
negative (a) and positive (b) mode, using the 9-AA matrix by averaging 2.000 consecutive laser shots. MALDI-TOF spectra of 9-AA matrix detected in 
negative (c) and positive mode (d) is reported. Spectra were acquired using a Ultraflex Extreme MALDI-TOF/TOF (Bruker).
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9-AA in negative mode are reported. As showed, overall 
lipid pattern appears very similar, dominated by signals 
in the range of 600–1,500 m/z compatible with phospho-
lipid species [21] as also identified by post-spectral pro-
cessing (Table 2).
Multivariate analysis of lipid species
The signals of the MALDI spectra were exported in a 
final matrix in a compatible format for the multivariate 
analysis with Simca-P+ software. In this matrix all mol-
ecules were reported as variables identified by its own m/z 
value related to each observation (patient). To obtain the 
maximum separation between the two clinical groups, 
all variables were processed by Partial Last Squares Dis-
criminant Analysis (PLS-DA). Figure  3a shows the PLS-
DA score plot of the first two principal components. The 
graph highlights the separation tendency between the MS 
(in red) and healthy (in black) groups based on their lipid 
profile. One MS sample (MS1) was dispersed among con-
trol subjects probably due to its low EDSS score (Table 1).
Interpreting a PLS-DA model with a lot of components 
and a multitude of response factors can be a complex 
task. In this model the most influential molecules respon-
sible for the separation between classes are variables that 
have the greatest influence in PLS-DA. Simca-P+ soft-
ware generates a list of all metabolite analyzed, sorted 
by a score number named VIP. The VIP score reflects 
the variable’s contribution on the classification, and so 
can be used to discover the most relevant differential 
metabolites for the group separation. Lipid molecules 
with a VIP score greater than 1 were taken in consid-
eration to evaluate their significance in the univariate 
statistical analysis by comparing the relative intensity of 
each lipid molecules through a t-test or Mann–Whitney 
test between the two clinical groups in order to confirm 
their ability to discriminate MS patients from healthy 
controls. Four metabolites showed a significant p-value 
(p-value <0.05) between MS patients and healthy con-
trols: m/z 861,640 that, on the basis of our assignment 
(Table  2), corresponded to two possible molecular spe-
cies namely phosphatidylglycerol or phosphatidylinositol 
(respectively PG 42:0 or PI 36:2); m/z 911,618 identified 
as phosphatidylinositol (PI 40:6); m/z 1,448,140 and m/z 
1,472,170 identified as cardiolipins (respectively as CL 
Figure 2 MALDI-TOF mass spectra of CD4+ lipids from MS and control subjects obtained in negative mode. Representative negative ion MALDI-
TOF spectrum of total lipid extracts from healthy controls (a) and multiple sclerosis patients (b) CD4+ T lymphocytes, using the 9-AA matrix by 
averaging 2.000 consecutive laser shots.
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72:8 and CL 74:10). Due to the presence of various iso-
mers, some identified molecular species were classified 
only on the basis of their class, the total number of the 
carbons in lateral chains and the total number of dou-
ble bonds (unsaturation). These results are summarized 
in the Table 3 while the histogram in the Figure 3 shows 
the intensity of each differential expressed metabolite 
between the two clinical groups.
MS/MS spectra of cardiolipin
To confirm the identities of cardiolipin species, samples 
spectra were compared to those of a cardiolipin stand-
ard. As reported in the Figure 4, mass spectra of sample 
in the range of cardiolipin species (Figure 4a) were almost 
overlapping with those of the standard (Figure  4b). In 
addition, the MS/MS spectra of the ion m/z 1.448,140, 
was selected for fragmentation to further support the pro-
posed assignment of cardiolipin. According to [22] the 
MS/MS spectra of cardiolipin [M-H]− (Figure 4c) gener-
ated the following ions: two fragments at m/z 78,911 and 
96,971 corresponding to phosphate and dihydrogen phos-
phate ions respectively; the peak at m/z 153,117 which 
corresponds to the neutral loss of glycerol-3-phosphate; 
the peak at m/z 279,496 identified as linoleic acid (C18:2), 
the m/z 415,515 assigned to the lyso-form of phosphatidic 
acid and the m/z 695,750 that corresponds to the phos-
phatidic acid with 18:2/18:2 fatty acyl groups.
Fatty acid profile of CD4+ T cells by gas‑chromatographic 
analysis
As a complement to MALDI-TOF analysis of phospho-
lipids, we decided to perform a gas-chromatographic 
fatty acid comparative profiling of CD4+ T cells from 
MS patients and healthy subjects. Phospholipids consist 
of fatty acids and a significant correlation between the 
fatty acid composition of lymphocytes and the capacity 
of these cells to produce eicosanoids involved in immu-
noregulation has been established [23]. However, very lit-
tle is known about the fatty acid composition of CD4+ T 
cells from MS patients.
As shown in Table  4, the total amount of saturated 
fatty acids was decreased in MS with respect to control 
subjects whereas both monounsaturated and polyunsat-
urated fatty acids were increased in MS. Among polyun-
saturated fatty acids those of n-6 series were responsible 
for the augmented value. These findings well correlate 
with data obtained by MALDI-TOF demonstrating that 
MS-induced lipid compositional changes occur at the 
molecular-specie level.
Discussion
There is growing evidence that MALDI-TOF is an excel-
lent analytical technique for a rapid screening of lipids 
in biological matrices due to its high sensitivity and 
rapid sample preparation [20, 24]. Thus, by using this 
approach, individual molecular species including low-
abundance phospholipid classes could be easily analyzed 
even in total lipid extracts [20] and directly on tissue 
slices without any prior step of extraction [12]. Despite all 
these potentialities, some limitations exist. Due to their 
compositional complexity, the identification of individual 
species at high-resolution appear to be fundamental for 
the unambiguous mass assignment of lipids in complex 
samples [25]. For this reason, high-resolution mass spec-
trometers have become the preferred approach for the 
identification and quantification of total lipid extracts in 
top-down lipidomic experiments [25].
Table 2 Assignment based on m/z measurements of peaks 
detected in  the negative ion mass spectra of  lipids 
from CD4+ T lymphocytes using 9-AA as matrix
For the identification, mass tolerance was set to ±0.1.
CL cardiolipin, DG diacylglycerol, PA phosphatic acid, PE 
phosphatidylethanolamine, PS phosphatidylserine, PI phosphatidylinositol, PG 
phosphatidylglycerol, SM sphingomyelin.
m/z value Assignment [M‑H]− m/z value Assignment [M‑H]−
513,400 Matrix 799,767 SM d17:1/24:0 or 
d18:1/23:0
529,389 Matrix 800,596 PE 41:0 or PS 37:2
573,412 Matrix 802,607 PE 42:6 or PS 38:1
617,430 Matrix 806,584 PE 42:4
618,557 Matrix 808,601 PE 41:4 or PS 38:5
619,371 PA 30:0 826,604 PE 42:2
666,141 Matrix 828,631 PE 42:1
687,632 DG 41:3 836,632 PE 43.4 or PS 40:5
722,603 PE 36:4 850,617 PE 44:4 or PS 42:4
738,599 Sphyngolipid 15:2/22:0 852,631 PE 44:3
742,634 PE 36:2 857,625 PG 42:2
743,696 SM 37:1 859,642 PI 36:2
744,652 PE 36:1 861,640 PG 42:0 or PI 36:2
746,600 PE 36:0 883,642 PI 38:5
750,636 Sphyngolipid 18:2/20:1 885,661 PG 44:2
760,934 PE O-38:0 901,657 PI 40:2
764,619 PE 38:5 909,663 PI 40:6
766,634 Sphyngolipid 18:2/21:0 911,618 PI 40:6
769,716 PA 42:1 or SM 39:0 913,696 PI 40:4
771,732 PA 42:0 or SM 38:1 943,623 PI 42:3
776,849 PE O-40:6 or PS O-36:0 1.448,140 CL 72:8
778,651 PE 40:4 1.470,150 CL 74:11
780,560 PE 41:4 1.472,170 CL 74:10
782,562 PE 41:3 1.494,150 CL 75:6
792,650 PE 40:5 1.496,170 CL 75:5
794,675 Sphingolipid 18:2/23:0 1.498,190 CL 75:4
795,736 PI O-32:0
797,754 SM d17/24:1
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In this study, we reported a direct MALDI-TOF analy-
sis of total lipid extracts from CD4+ T lymphocytes using 
9-AA as a matrix in negative mode. Compared to positive 
ion spectra, negative spectra displayed a higher amount 
of signals allowing the identification of several lipid spe-
cies mostly phospholipids (DG, PA, PG, PE, PS, PI, CL 
and sphingomyelin). Moreover, the analysis of spectrum 
in the negative mode is facilitated by the exclusive pres-
ence of deprotonated [M-H]− ion signals [26].
The interest in lipids and their analysis in the field of 
MS were already demonstrated by Del Boccio and col-
leagues [27] that showed and altered lipid pattern in the 
serum of MS patients. Here, for the first time, a mass-
spectrometry approach was applied for the characteriza-
tion of lipids from CD4+ T lymphocytes.
Lipids play a critical role in the structure of the cen-
tral and peripheral nervous systems in particular at the 
cell membrane level [28]. Alterations in the phospholipid 
as well as in plasma membrane fatty acid composition, 
modifying the membrane fluidity, can affect a wide range 
of cellular functions such as ligand-receptor signal trans-
duction and membrane trafficking with consequences on 
cell functions and survival [29]. In red blood cells from 
Figure 3 Partial least squares discriminat analysis. Partial least squares discriminat analysis (PLS-DA) score plot from lipidomics data derived from 
control (black triangle) and MS (red circle) patients. Below, histograms show peaks that were significantly different (P < 0.05) among groups. Data 
reported as mean ± SD.
Table 3 Metabolites whcich allowed the separation 
between  healthy and  multiple sclerosis patients selected 
on the the basis of VIP
A P value <0.05 was set as the threshold to define significant differences.
m/z Regulation in MS P value Ion Lipid species
861,640 Up-regulated 0.037 [M-H]− PG 42:0 or PI 36:2
911,618 Up-regulated 0.042 [M-H]− PI 40:5
1.448,140 Up-regulated 0.042 [M-H]− CL 72:8
1.472,170 Up-regulated 0.047 [M-H]− CL 74:10
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MS patients, alterations in the membrane fluidity closely 
correlated with inflammation and disease outcome [29]. 
Moreover, modifications in membrane fluidity have been 
reported in the central nervous system of patients with 
motor neuron disease [28] as well as in the brain cortex 
and spinal cord of patients affected by amyotrophic lat-
eral sclerosis [30]. Despite the importance of lympho-
cytes in the context of MS, the lipid metabolism of these 
cells has received less attention. A large body of evidence 
indicate that CD4+ T cells play a role in MS pathogenesis 
[4], as these cells have the ability to damage and cross the 
blood–brain barrier, inducing axonal damage and neu-
ronal death [6]. Lymphocytes are then important players 
in the onset and evolution of the disease and the main 
target of the current immunological therapies including 
interferon β reagents, glatiramer acetate, natalizumab, 
rituximab and Copaxone. Understanding which biologi-
cal and biochemical alterations characterize lymphocytes 
of MS patients may be important for the identification of 
new biomarkers of disease and for the development of 
future therapies.
Our analysis by MALDI-TOF of lipid extracted from 
CD4+ T cells highlights a characteristic phospholipid 
pattern in MS and HC patients (Table 2). Through a mul-
tivariate statistical analysis we found several discrimi-
nant signals between the two groups (Figure 2). Among 
these, phospholipids in the range of 1,200–1,500  m/z 
were unambiguous identified as cardiolipins. How-
ever since the small sample size the potentiality of these 
lipids, to serve as prospective biomarkers, should be 
further confirmed and validated in a targeted and more 
extensive clinical study. In mammalian cells, cardiolipin 
Figure 4 MS/MS based characterization of the cardiolipin m/z 
1,448,14 ion. Representative MS spectra of cardiolipin species 
obtained from a MS sample (a), and from cardiolipin standard (b). 
Following MS/MS of the 1,448,14 cardiolipin generated fragment ions 
were illustrated (c); cardiolipin structure is reported in the insert.
Table 4 Fatty acid composition of CD4+ T lymphocytes
Fatty acids were obtained from whole CD4+  T lymphocytes as reported in the 
“Methods” section. Values are expressed as percentage of total fatty acids.
MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, SFA 
saturated fatty acids, UI Unsaturation index.
Values are given as mean ± SD. 
* P < 0.05; ** P < 0.01; *** P < 0.001.
Fatty acids HC MS
14:0 1.5 ± 0.6 1.9 ± 0.7
16:0 34.3 ± 1.2 31.8 ± 2.0
16:1 0.2 ± 0.08 0.3 ± 0.09
18:0 57.2 ± 1.2 54.2 ± 4.0
18:1n-9 3.1 ± 0.5 5.6 ± 1.7*
18:1n-11 0.7 ± 0.06 0.9 ± 0.08**
18:2n-6 1.4 ± 0.2 2.0 ± 0.7
18:3n-3 0.5 ± 0.03 0.3 ± 0.01**
20:4n-6 1.5 ± 0.1 4.4 ± 0.2**
Σ SFA 92.9 ± 0.6 86.9 ± 4.3***
Σ MUFA 3.3 ± 0.2 5.8 ± 1.7***
Σ PUFA 3.3 ± 0.4 6.7 ± 0.9**
Total n-6 2.8 ± 0.9 6.4 ± 0.3**
SFA/PUFA 14.4 ± 1.7 7.9 ± 3.8***
UI 13.7 ± 3.2 29.1 ± 11.6***
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is located almost exclusively in the inner mitochondrial 
membrane where it accounts for 10–20% of total mito-
chondrial lipids. Cardiolipin is essential for the optimal 
function of numerous enzymes that are involved in the 
mitochondrial energy metabolism [31]. Moreover, cardi-
olipin molecules could be also expressed on the surface 
of apoptotic cells and thus recognized by antiphospho-
lipid antibodies [32]. Regarding this aspect, it has been 
reported that during mitochondrial stress or damage, the 
asymmetric cardiolipin distribution collapses resulting in 
its externalization to the outer mitochondrial membrane, 
leading to signalling events essential for mitophagy and 
apoptosis [33]. Interestingly, anti-cardiolipin antibodies 
were detected and measured in the plasma of some MS 
patients [34].
Several hypotheses can be considered to explain the 
alteration of cardiolipin observed by MALDI in MS 
patients. Mitochondrial dysfunction has been impli-
cated in the development and progression of MS [35], so 
closely to propose mitochondrial-targeted approaches for 
the treatment of the disease [36]. In particular, Witte and 
collaborators [35] described how an enhanced density of 
mitochondria in MS lesions might contribute to the for-
mation of free radicals and subsequent tissue damage. In 
light of our results, higher intensity of cardiolipin signal 
in MS patients may indicate a possible higher amount of 
mitochondria in these cells. The increase in the number 
of mitochondria may be also a strategy to prevent the 
decline of mitochondrial efficiency [37], as we recently 
observed for damaged mitochondria in cirrhotic rat liv-
ers [38].
It is well known that in most mammalian tissues car-
diolipin acyl composition is predominantly comprised 
of 18-carbon unsaturated acyl chains, the vast major-
ity of which is linoleic acid (C18:2, n-6) [33]. In our study 
an increased amount of cardiolipin rich in PUFA were 
described. PUFA are important molecules not only as 
structural constituent of plasma membrane, but also as 
mediators of inflammation. To this end, n-6 PUFA are 
substrates of cyclooxygenase (COX) and lipoxygenase 
(LOX) [39] enzymes which can convert PUFA in pro-
inflammatory molecules such as prostaglandins (PG) 
of series 2 and leukotrinene (LT) of the series 4. An 
increased amount of PGE2 in the serum and cerebrospi-
nal fluid of patients affected by amyotrophic lateral scle-
rosis was observed [40]. Moreover, LTC4, D4, E4, F4 are 
potent chemotactic agents contributing to neuroinflam-
mation by enhancing vascular permeability [41]. Our 
gas-chromatographic analysis of CD4+ T cells revealed 
an increase in PUFA of the n-6 series as well as in the 
unsaturation index (UI) in MS with respect to HC. These 
data well correlate with the results of MALDI-TOF.
Many studies have associated the progression of patho-
logical conditions with changes in the fatty acyl moieties 
of cardiolipin [22]. Shifting of fatty acids in myocardial 
cardiolipin from saturated fatty acids to highly unsatu-
rated species was linked to the onset of heart failure in 
spontaneous hypertensive rats [42]. Moreover, we should 
also consider that phospholipids with saturated fatty acid 
side chains have been indicated as natural anti-inflamma-
tory class of compounds that ameliorated experimental 
autoimmune encephalomyelitis by suppressing activation 
and inducing apoptosis of autoreactive T cells [43].
Conclusion
Taken together, our data obtained by a lipidomic 
approach can suggest an altered mitochondrial lipid 
metabolism in CD4+ T cells from MS patients. The small 
number of patients represents a weakness of this prelimi-
nary study and may limit a rapid clinical application of 
our results. Further studies enrolling a larger cohort of 
patients are needed to confirm our finding and to propose 
a functional link about the possible role of mitochondria 
on the regulation of lymphocyte lipid metabolism in MS. 
In this context, the feasibility of MALDI-TOF/TOF in 
the rapid screening and characterization of lipid samples 
makes these results useful for potential scale-up to larger 
patient populations.
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